The White House has officially withdrawn its nomination of Heidi Overton to lead the Food and Drug Administration, a move confirmed by administration officials to The Guardian. This decision comes just one day before a scheduled vote in the Senate Health Committee, where Republicans hold a razor-thin one-vote majority.
Overton, a physician and prominent opponent of abortion rights, was nominated in August by President Donald Trump. Her selection was viewed by some as an effort to install a stabilizing Trump loyalist following a tumultuous year under former commissioner Marty Makary. However, the nomination faced significant hurdles, leading to its retraction.
According to The Hill and NewsNation, the withdrawal was driven by opposition from Senate Republicans. Despite the party's control of the committee, the narrow margin suggests that securing the necessary votes for Overton's confirmation was deemed unfeasible. Consequently, the White House chose to pull the nomination rather than face a likely defeat.
In related personnel news, the Department of Defense continues to navigate leadership transitions. Defense Secretary Pete Hegseth recently nominated Gen. Christopher LaNeve to lead the Army, a move that follows months of delay, as reported by The New York Times. Separately, Acting Navy Secretary Hung Cao is set to appear before the Senate Armed Services Committee on Tuesday to seek permanent confirmation, following the ouster of former Secretary John Phelan.
These developments highlight the ongoing challenges in aligning executive nominations with legislative realities. The FDA withdrawal underscores the difficulty of advancing candidates with specific ideological profiles in a closely divided Senate, while the military appointments reflect the administration's continued push to reshape defense leadership.